** Shares of drug developer iTeos Therapeutics ITOS.O rise 25.09% to $10.67 premarket
** Co says it plans to leverage its cash reserves to deliver near-term shareholder value as it winds down operations and explore sale of key assets as part of a strategic review
** As of last close, co's market cap was $326.48 million vs its cash balance of $624.3 million as of March 31
** Co's potential asset sale may include experimental cancer drugs and preclinical obesity program
** Earlier this month, co and GSK GSK.L stopped the development of an experimental lung cancer drug, belrestotug, after it failed to stop the disease from progressing in two studies
** Up to last close, stock up ~11% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。